

## OLMETOR

**For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory**

Abbreviated Prescribing information for OLMETOR (Olmesartan Medoxomil 20,40mg tablets)[Please refer the complete prescribing information available at [www.torrentpharma.com](http://www.torrentpharma.com)

**PHARMACOLOGICAL PROPERTIES:** - Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle.

**INDICATION:** For the treatment of mild to moderate hypertension

**DOSAGE AND ADMINISTRATION:** The usual recommended starting dose of Olmesartan is 20 mg once daily when used as monotherapy in patients who are not volume-contracted. For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Olmesartan may be increased to 40 mg. For **Pediatric Hypertension (6 to 16 years of age)** dosage must be individualized. For children who can swallow tablets, the usual recommended starting dose of Olmesartan is 10 mg once daily for patients who weigh 20 to <35 kg (44 to 77 lb), or 20 mg once daily for patients who weigh  $\geq 35$  kg.

**CONTRAINDICATION:** Do not co-administer aliskiren with Olmesartan in patients with diabetes

**WARNINGS & PRECAUTIONS:** **Fetal toxicity** use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. **Morbidity in Infants** children <1 year of age must not receive Olmesartan for hypertension. Drugs that act directly on the renin-angiotensin aldosterone system (RAAS) can have effects on the development of immature kidneys. In patients with an activated renin-angiotensin aldosterone system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may be anticipated after initiation of treatment with Olmesartan. Impaired Renal Function, Sprue-like Enteropathy severe, chronic diarrhea with substantial weight loss has been reported in patients taking olmesartan months to years after drug initiation.

**DRUG INTERACTIONS:** NSAIDS, colesevelam hydrochloride and Lithium.

**ADVERSE REACTIONS:** Chest pain, peripheral edema, vertigo, abdominal pain, dyspepsia, gastroenteritis, nausea, tachycardia, hypercholesterolemia, hyperlipemia, hyperuricemia, elevations of liver enzymes and/or serum bilirubin were observed infrequently, adult hypertension, asthenia, dizziness, flushing, palpitation, somnolence, angioedema, anaphylactic reactions, peripheral edema, vomiting, diarrhea, rhabdomyolysis, alopecia, pruritus, urticaria, gynecomastia, jaundice and hepatic enzyme elevations.

**MARKETED BY:**



TORRENT PHARMACEUTICALS LTD.

Torrent House, Off Ashram Road,  
Ahmedabad-380 009, INDIA

**IN/OLMETOR 20,40mg/Oct-2015/01/AbPI**  
(Additional information is available on request)